Vanguard Capital Management
XLO icon

Vanguard Capital Management’s Xilio Therapeutics XLO Stock Holding History

Vanguard Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
178,517
+54,857
+44% +$458K ﹤0.01% 3467
2026
Q1 		$1.04M Buy
+123,660
New +$1.01M ﹤0.01% 3543

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's XLO Position: Q2 2026 in Review

Vanguard Capital Management increased its Xilio Therapeutics (XLO) stake by 44% in Q2 2026, buying an estimated $458K and bringing the position to 178,517 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Vanguard Capital Management first reported a position in XLO in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Vanguard Capital Management held 178,517 shares of Xilio Therapeutics worth $1.71M as of Q2 2026.
  • Vanguard Capital Management bought 54,857 Xilio Therapeutics shares in Q2 2026, an estimated $458K.
  • Xilio Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3467 holding.
  • Vanguard Capital Management first reported a position in Xilio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.